Literature DB >> 17339566

Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease.

Whady Hueb1, Neuza Helena Lopes, Bernard J Gersh, Paulo Soares, Luiz A C Machado, Fabio B Jatene, Sergio A Oliveira, Jose A F Ramires.   

Abstract

BACKGROUND: Despite routine use of coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI), no conclusive evidence exists that either modality is superior to medical therapy (MT) alone for treating multivessel coronary artery disease with stable angina and preserved ventricular function. METHODS AND
RESULTS: The primary end points were total mortality, Q-wave myocardial infarction, or refractory angina requiring revascularization. The study comprised 611 patients randomly assigned to undergo CABG (n=203), PCI (n=205), or MT (n=203). At the 5-year follow-up, the primary end points occurred in 21.2% of patients who underwent CABG compared with 32.7% treated with PCI and 36% receiving MT alone (P=0.0026). No statistical differences were observed in overall mortality among the 3 groups. In addition, 9.4% of MT and 11.2% of PCI patients underwent repeat revascularization procedures compared with 3.9% of CABG patients (P=0.021). Moreover, 15.3%, 11.2%, and 8.3% of patients experienced nonfatal myocardial infarction in the MT, PCI, and CABG groups, respectively (P<0.001). The pairwise treatment comparisons of the primary end points showed no difference between PCI and MT (relative risk, 0.93; 95% confidence interval, 0.67 to 1.30) and a significant protective effect of CABG compared with MT (relative risk, 0.53; 95% confidence interval, 0.36 to 0.77).
CONCLUSIONS: All 3 treatment regimens yielded comparable, relatively low rates of death. MT was associated with an incidence of long-term events and rate of additional revascularization similar to those for PCI. CABG was superior to MT in terms of the primary end points, reaching a significant 44% reduction in primary end points at the 5-year follow-up of patients with stable multivessel coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17339566     DOI: 10.1161/CIRCULATIONAHA.106.625475

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  53 in total

Review 1.  Developmental actions of natriuretic peptides in the brain and skeleton.

Authors:  J A Waschek
Journal:  Cell Mol Life Sci       Date:  2004-09       Impact factor: 9.261

2.  Best way to revascularize patients with main stem and three vessel lesions: patients should undergo PCI!

Authors:  Volker Schächinger; Christian Herdeg; Bruno Scheller
Journal:  Clin Res Cardiol       Date:  2010-07-08       Impact factor: 5.460

3.  PCI or CABG: which patients and at what cost?

Authors:  Tony Gershlick; Martyn Thomas
Journal:  Heart       Date:  2007-10       Impact factor: 5.994

4.  Revascularization treatment in patients with coronary artery disease.

Authors:  S G Foussas; G Z Tsiaousis
Journal:  Hippokratia       Date:  2008-01       Impact factor: 0.471

5.  Cost-effectiveness of coronary artery bypass graft and percutaneous coronary intervention compared to medical therapy in patients with coronary artery disease: a systematic review.

Authors:  Saeed Sheikh Gholami; Farbod Ebadi Fard Azar; Aziz Rezapour; Masih Tajdini
Journal:  Heart Fail Rev       Date:  2019-11       Impact factor: 4.214

6.  Coronary revascularization in diabetic patients: Current state of evidence.

Authors:  Mukesh Singh; Rohit Arora; Vamsi Kodumuri; Sandeep Khosla; Evyan Jawad
Journal:  Exp Clin Cardiol       Date:  2011

Review 7.  Percutaneous versus surgical interventions for coronary artery disease in those with diabetes mellitus.

Authors:  Ozlem Soran
Journal:  Curr Cardiol Rep       Date:  2013-01       Impact factor: 2.931

8.  Medical and Catheter-Based Therapies for Managing Stable Coronary Disease: Lessons From the COURAGE Trial.

Authors:  Dean J Kereiakes
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-02

Review 9.  Chronic coronary artery disease: diagnosis and management.

Authors:  Andrew Cassar; David R Holmes; Charanjit S Rihal; Bernard J Gersh
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

Review 10.  Optimal method of coronary revascularization in patients receiving dialysis: systematic review.

Authors:  Immaculate F Nevis; Anna Mathew; Richard J Novick; Chirag R Parikh; Philip J Devereaux; Madhu K Natarajan; Arthur V Iansavichus; Meaghan S Cuerden; Amit X Garg
Journal:  Clin J Am Soc Nephrol       Date:  2009-02       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.